Neurocrine Biosciences Inc. announced the presentation of data from their Phase 2 study of NBI-1117568, an investigational oral muscarinic M4 selective orthosteric agonist, at the American Society of Clinical Psychopharmacology 2025 Annual Meeting. The study involved adults with schizophrenia and demonstrated a significant improvement in symptoms and overall severity. The treatment was generally safe and well-tolerated, with adverse events such as somnolence and dizziness reported. Following these positive results, a Phase 3 registrational program has been initiated to further assess NBI-1117568's efficacy, safety, and tolerability. This global, double-blind, placebo-controlled trial is expected to enroll approximately 280 patients. The primary endpoint focuses on a reduction in the PANSS score, and additional information can be found on ClinicalTrials.gov.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.